Division of Breast Surgery, Department of Surgery, The University of Hong Kong, Hong Kong, China.
World J Surg. 2012 Apr;36(4):702-13. doi: 10.1007/s00268-011-1406-y.
BRCA1/2 mutation prediction models (BRCAPRO, Myriad II, Couch, Shattuck-Eidens, BOADICEA) are well established in western cohorts to estimate the probability of BRCA1/2 mutations. Results are conflicting in Asian populations. Most studies did not account for gender-specific prediction. We evaluated the performance of these models in a Chinese cohort, including males, before BRCA1/2 mutation testing.
The five risk models were used to calculate the probability of BRCA mutations in probands with breast and ovarian cancers; 267 were non-BRCA mutation carriers (247 females and 20 males) and 43 were BRCA mutation carriers (38 females and 5 males).
Mean BRCA prediction scores for all models were statistically better for carriers than noncarriers for females but not for males. BRCAPRO overestimated the numbers of female BRCA1/2 mutation carriers at thresholds ≥20% but underestimated if <20%. BRCAPRO and BOADICEA underestimated the number of male BRCA1/2 mutation carriers whilst Myriad II underestimated the number of both male and female carriers. In females, BRCAPRO showed similar discrimination, as measured by the area under the receiver operator characteristic curve (AUC) for BRCA1/2 combined mutation prediction to BOADICEA, but performed better than BOADICEA in BRCA1 mutation prediction (AUC 93% vs. 87%). BOADICEA had the best discrimination for BRCA1/2 combined mutation prediction (AUC 87%) in males.
The variation in model performance underscores the need for research on larger Asian cohorts as prediction models, and the possible need for customizing these models for different ethnic groups and genders.
BRCA1/2 突变预测模型(BRCAPRO、Myriad II、Couch、 Shattuck-Eidens、BOADICEA)在西方队列中已被广泛建立,用于估计 BRCA1/2 突变的概率。在亚洲人群中结果存在争议。大多数研究没有考虑到性别特异性预测。我们在进行 BRCA1/2 突变检测之前,在一个中国队列中评估了这些模型在男性中的表现。
使用这五个风险模型来计算患有乳腺癌和卵巢癌的先证者中 BRCA 突变的概率;267 例非 BRCA 突变携带者(247 例女性和 20 例男性)和 43 例 BRCA 突变携带者(38 例女性和 5 例男性)。
所有模型的 BRCA 预测评分平均值对于携带者来说均高于非携带者,无论男女均有统计学意义。BRCAPRO 在阈值≥20%时高估了女性 BRCA1/2 突变携带者的数量,但如果<20%时则低估了数量。BRCAPRO 和 BOADICEA 低估了男性 BRCA1/2 突变携带者的数量,而 Myriad II 则低估了男性和女性携带者的数量。在女性中,BRCAPRO 在 BRCA1/2 联合突变预测的接收者操作特征曲线(ROC)下面积(AUC)方面与 BOADICEA 具有相似的区分能力,但在 BRCA1 突变预测方面表现优于 BOADICEA(AUC 93%对 87%)。BOADICEA 对男性 BRCA1/2 联合突变预测的区分能力最佳(AUC 87%)。
模型性能的差异突出表明需要对更大的亚洲队列进行研究,以及可能需要针对不同种族和性别定制这些模型。